Last updated on July 2019

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)


Other Details:

For more information, please contact Incyte Corporation at 1.855.463.3463 or visit www.incyteclinicaltrials.com



Find a site near you

Start Over

Greenvile Health System

Located in: Greenvile, SC USA
  Connect »

Clinical Research Alliance

Located in: Lake Success, NY USA
  Connect »

Banner Health

Located in: Gilbert, AZ USA
  Connect »

Summit Medical Group

Located in: Morristown, NJ USA
  Connect »

University of Kansas Cancer Center

Located in: Kansas City, MO USA
  Connect »

Aarhus Universitets Hospital

Located in: Aarhus, Denmark
  Connect »

The Finsen Centre, National Hospital

Located in: Copenhagen, Denmark
  Connect »

FN Ostrava

Located in: Ostrava, Czech Republic
  Connect »

Azienda Ospedaliera Mater Domini

Located in: Catanzaro, Catanzaro Italy
  Connect »

Scripps Green Hospital

Located in: La Jolla, CA USA
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.